Clinical and biological impact of LINC02544 expression in breast cancer after neoadjuvant chemotherapy

Z.-H. Guo, L.-T. Yao, A.-Y. Guo

Department of Breast Surgery, the First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China. guoayao@yeah.net

---

• Oncology

OBJECTIVE: Analysis of breast cancer and cancer tissue after neoadjuvant chemotherapy (nCT) may be helpful to find new biomarkers. It is known that long non-coding RNAs (lncRNAs) are involved in the carcinogenic pathway and drug resistance of breast cancer. Our aim was to determine the role of LINC02544 in the behavior and outcome of post-nCT breast cancer.

PATIENTS AND METHODS: The expression level of LINC02544 in breast cancer and its effect on the survival time of patients were predicted by lnCAR database. In vitro, EdU, Wound-healing and transwell assays were used to detect the effects of LINC02544 on the proliferation, migration and invasion of MCF-7 cells, and the related regulatory networks were analyzed by the database. Quantitative Reverse Transcriptase-Polymerase Chain Reaction (QRT-PCR) was used to detect the expression of LINC02544 in 147 cases of nCT before and after treatment, and the relationship between the expression of LINC02544 and survival time and clinicopathological features was analyzed.

RESULTS: LINC02544 was highly expressed in breast cancer and led to poor prognosis. Overexpression of LINC02544 promoted proliferation, invasion and migration of breast cancer cells. Compared with the residual tumor after nCT with low expression of LINC02544, the high expression of LINC02544 in the residual tumor after nCT was significantly correlated with overall survival and disease-free survival.

CONCLUSIONS: In this study, it is suggested that LINC02544 has a potential application prospect as a biomarker and therapeutic target for breast cancer patients and neoadjuvant therapy patients.

 

Free PDF Download